PepGen, Inc. announced approval by Health Canada of PepGen’s Clinical Trial Application (CTA) authorizing initiation of first-in-human trials of PepGen’s lead Enhanced Delivery Oligonucleotide (EDO) candidate, PGN-EDO51, to treat individuals with Duchenne muscular dystrophy.
[PepGen, Inc.]
Sorry, but the selected Zotpress account can't be found.
